GPS Air recognizes the importance of transparency regarding the legal aspects of its pioneering ionization technology, particularly during a period marked by the COVID-19 pandemic. Historical accounts dating back to this challenging time may reference legal disputes, which are now addressed with clarity and factual grounding.
During an era when misinformation was rampant, GPS Air steadfastly defended its proprietary needlepoint bipolar ionization (NPBI) technology against unfounded claims. However, it is important to note that these outdated reports and stories do not reflect current knowledge or scientific opinion of GPS Air technology. GPS Air was the first to demonstrate the efficacy of its products against SARS-CoV-2, as well as adhering to safety standards like UL 2998, certifying its technology as ozone-free and safe.
Competitor misinformation campaigns resulted in GPS Air becoming the target of frivolous lawsuits filed by professional plaintiffs seeking to capitalize on the confusion. Nonetheless, GPS Air addressed the misinformation head-on through legal action, notably resolving a lawsuit that cleared misconceptions of the company's technology.
The main defendant clarified in a public statement that her prior statements were NOT applicable to GPS Air products as our NPBI technology utilizes soft ionization, which sets it apart from other ionization technologies which may produce harmful byproducts. GPS Air technology is also certified ozone free under UL2998, unlike other technologies. The negative statements posted by the defendants, including the open letter, have been removed from the public domain. In addition, several media outlets retracted or refused to air further false stories following revelations in the lawsuit.
GPS Air takes pride in delivering a technology that has seen more than 250,000 successful installations from Google to Boston Children’s Hospital. Users such as Houston Methodist Hospital, Novant Health, and Johns Hopkins protect sensitive occupant populations with our products. Our unwavering commitment to scientific leadership in the IAQ space underscores our dedication to improving the air we breathe and making the spaces we live and work in healthier.
By investing heavily in independent third-party lab testing, GPS Air has amassed the most comprehensive performance data in the industry, specifically in large chamber formats. Peer-reviewed scientific journal articles have recognized the particle removal, safety, and efficacy of our needle point bipolar ionization (NPBI) soft ionization.
This testing is at the heart of our solutions, ensuring that our products not only comply with, but also set industry benchmarks for safety and performance—including international standards like UL2998 and ASHRAE Standard 241.
GPS Air extends an open invitation to friends and skeptics alike to visit our Research & Development facility in Charlotte, NC, where our expert laboratory team is poised to showcase the intricacies of NPBI technology. We look forward to discussing any concerns and demonstrating how our approach eclipses competing technologies in both efficacy and safety.
For further inquiries or to plan a visit to our facility, please reach out to us at:
GPS Air, Inc.
3101 Yorkmont Road, Suite 1500
Charlotte, NC 28208
marketing@gpsair.com
